id : NIHR135657

award_type : Research

award_title : Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]

award_amount : 70000

award_amount_disp : 70,000.00

app_abstract : To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for adjuvant treatment of resected non-small-cell lung cancer.

app_plain_english_summary : Lung cancer is the third most common cancer and the most common cause of cancer death in the UK, accounting for 13% of all new cancer cases and 21% of all cancer deaths in 2018. [1] There are around 39,340 new lung cancer cases and 27,682 deaths from lung cancer in the England every year. Up to 85% of lung cancers are non-small-cell lung cancers (NSCLC).[2] Most lung cancers are diagnosed at an advanced stage, when the cancer has spread to lymph nodes and other organs in the chest (locally advanced disease; stage III) or to other parts of the body (metastatic disease; stage IV). Less than 30% of lung cancers are diagnosed at an early stage (stage 1 or 2). NICE guideline Lung cancer: diagnosis and management recommends surgery, radiotherapy, chemoradiotherapy or a combination of these for early stage disease.[3] Around 18% of people with NSCLC had surgical resection with curative intent in England and Wales in 2017.[4] If well enough, people may be offered a cisplatin-based chemotherapy (adjuvant treatment) after surgery.[3] People are actively monitored for cancer recurrence. If the cancer comes back, treatment options and prognosis depend on the site of the recurrence. Despite the curative intent of treatment for early-stage lung cancer, survival is poor, with only about 57% people with stage I, 34% with stage II and 13% with stage III surviving for 5 years after diagnosis.[1] NICE technology appraisal guidance TA761 recommends osimertinib for use within the Cancer Drugs Fund as adjuvant treatment after complete tumour resection in adults with stage IB to IIIA NSCLC whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations. It is estimated that over half of all NSCLCs express the programmed cell death ligand-1 (PD-L1) biomarker.[5] Cancer cells expressing PD-L1 are believed to suppress certain immune responses and cause increased tumor aggressiveness. References 1. Lung cancer statistics. Cancer Research UK. Accessed March 2022 2. Types of lung cancer. Cancer Research UK. Accessed March 2022 3. Lung cancer: diagnosis and management. (2019) NICE guideline 122 4. National Lung Cancer Audit: Annual report 2018 (for the audit period 2017) (2020). Royal College of Physicians. Accessed March 2022. 5. Skov, B., Rørvig, S., Jensen, T. et al. (2020) The prevalence of programmed death ligand-1 (PD-L1) expression in non-small cell lung cancer in an unselected, consecutive population. Mod Pathol 33, 109 117

research_type : Evidence Synthesis

programme : Technology Assessment Reviews

funding_stream : NICE-TAR

award_status : Contracted

programme_stream : Commissioned

contracting_org : Kleijnen Systematic Reviews Ltd

centre : NETSCC

contracting_org_title : Contracting Organisation

start_date : 2024-03-13T23:59:59.000+0000

end_date : 2024-08-07T23:59:59.000+0000

lead_investigator_title : Chief Investigator

lead_investigator_name : Dr Robert Wolff

lead_investigator_orcid :

research_call : Batch 84

call_id : 22/07

link_type : Nice Guidance

link_title : NICE Guidance

link_URL : https://www.nice.org.uk/guidance/indevelopment/gid-ta10784

link_group : Impact

link_date_year : 0

link_date : 1900-01-01T23:59:59.000+0000

award_website :

funder : NIHR (non-ODA)

additional_funder :

jl_rep_title : Journals Library Report

highlighting :

full_contracting_org : Kleijnen Systematic Reviews Ltd

_version_ : 1780177600894730200

start_year : 2024

full_lead_investigator_name : Dr Robert Wolff